4.435USD+0.80%Mkt Cap: 1.61B USDP/E: —Last update: 2026-05-26
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.61B USD
Enterprise Value967.46M USD
Revenue (TTM)204.73M USD
Gross Profit33.99M USD
Net Income (TTM)-130.77M USD
Revenue/Share1.411 USD
Last Price4.435 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees416
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-43.17
PEG—
EV/EBITDA-25.44
EV/Revenue4.73
P/S8.07
P/B3.12
EPS (TTM)-0.71
EPS (Forward)-0.10
52W Range
1.99081% of range4.995
52W High4.995 USD
52W Low1.990 USD
Profitability
Gross Margin18.30%
Oper. Margin1.09%
EBITDA Margin-18.57%
Profit Margin-70.41%
ROE-61.58%
ROA-16.97%
Growth
Revenue Growth40.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-57.57M USD
CapEx (TTM)13.15M USD
FCF Margin-5.54%
FCF Yield-0.70%
Net Debt149.11M USD
Net Debt/EBITDA-3.92
Balance Sheet
Debt/Equity1.72
Current Ratio5.91
Quick Ratio4.68
Book Value/Sh1.434 USD
Cash/Share1.125 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Target (Mean)5.700 USD
Target Range5.000 USD – 6.000 USD
# Analysts5
Ownership
Shares Out.147.51M
Float102.60M
Insiders11.71%
Institutions88.42%
Short Interest
Short Ratio4.8d
Short % Float7.15%
Short % Out.6.02%
Shares Short8.88M
Short (prev mo.)9.51M
Technical
SMA 503.522 (+25.9%)
SMA 2003.276 (+35.4%)
Beta0.62
S&P 52W Chg28.31%
Avg Vol (30d)2.51M
Avg Vol (10d)3.43M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—